Emerging Life-Sciences Markets: New Partnerships, New Competitors

Article

Aging populations and increased access to healthcare translates into opportunities for biopharmaceutical companies. JLL’s 2015 Life Sciences Outlook report highlights global clusters worth watching.

BioPharm International

eBooks Volume 28, Issue 14  

Distant destinations have never looked better for multinational and middle market life-sciences companies. While multinationals fill their innovation pipelines in North America, branded and generic-drug producers alike are finding fertile ground for growth in new markets in Asia and Latin America.   Read this article and other articles in

BioPharm International

's 2015

The Future of Bioprocessing

eBook.    

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Related Content
Resignation concept in a professional office setting | Image Credit: © Jane Kelly - stock.adobe.com

FDA Shake-Up: Vinay Prasad Exits Amid Tumult in Biologics Oversight

Christopher Cole
July 30th 2025
Article

Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.

OleksKao - stock.adobe.com

AstraZeneca’s Imfinzi Advances in Gastric Cancer With FDA Priority Review

Christopher Cole
July 28th 2025
Article

Imfinzi’s application is supported by Phase III trial data showing improved pathologic complete response in early-stage gastric cancer.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF

Susan Haigney
July 25th 2025
Article

The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.

Light bulb drawing as symbol of idea on chalkboard | Image Credit: © New Africa -stock.adobe.com

Manufacturing and CMC Challenges in Immunotherapy: Lessons from Recent Complete Response Letters

Christopher Cole
July 25th 2025
Article

FDA’s recent CRLs for Replimune’s RP1 and others spotlight growing scrutiny on manufacturing, analytical rigor, and tech transfer in immunotherapy development.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

FDA Extends Review Period for GSK’s Blenrep

Susan Haigney
July 23rd 2025
Article

The agency has extended the review period for GSK’s biologics license application for belantamab mafodotin-blmf for the treatment of relapsed/refractory multiple myeloma.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

CGT Catapult Invests in Spliceor Trans-Splicing Gene Therapy Platform

Susan Haigney
July 22nd 2025
Article

The investment is part of CGT Catapult’s Cross-Catapult Investment Pilot and will accelerate the pre-clinical development of Spliceor’s trans-splicing gene therapy platform.

© 2025 MJH Life Sciences

All rights reserved.